Compare iShares MSCI United Kingdom (FTSE) (EWU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.52 (market cap $3.62B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.8× iShares MSCI United Kingdom (FTSE)'s market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares MSCI United Kingdom (FTSE) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EWU | XBI | |
|---|---|---|
Market Cap | $3.62B | $10.11B |
Volume | 923,896 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $49.39 | $169.55 |
52-Week Low | $41.34 | $104.99 |
Typical Hold Time | 46 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.23, up 0.65% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is testing key support at $46 amid rising UK gilt yields and inflation concerns. Recent UK housing policy announcements have boosted related sectors, but broader European economic pressures and ECB rate hikes create headwinds for the UK-focused ETF.
The outlook remains cautious given technical weakness and macroeconomic pressures from rising interest rates and energy prices. Investment opportunity exists if housing stimulus gains traction, but risks include prolonged inflation and further ECB tightening that could pressure UK equities.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
